We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stratagene Acquires Rights to microRNA Sequences
News

Stratagene Acquires Rights to microRNA Sequences

Stratagene Acquires Rights to microRNA Sequences
News

Stratagene Acquires Rights to microRNA Sequences

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stratagene Acquires Rights to microRNA Sequences "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stratagene Corporation has announced that it has obtained the last of the four co-exclusive licenses to more than 150 microRNA sequences available from Max Planck Innovation, the technology transfer agency of the Max Planck Society.

Under the terms of the agreement, Stratagene will have the right to use the microRNA sequences for the development, manufacture and sale of molecular diagnostic kits.

MicroRNAs are naturally occurring, small RNAs that act to regulate messenger RNA, or mRNA, expression in humans. Currently there are in excess of 300 microRNA’s identified and research in this field is likely to push this number much higher.

MicroRNAs are believed to regulate many genes, and thus are thought to be good indicators for biomarkers that are associated with many diseases. Of particular interest to Stratagene is the association of microRNAs with cancer.

"We are very excited to move into the microRNA area. The potential of these sequences, when paired with our proprietary FullVelocity technology, should allow us to develop important detection tests for the molecular diagnostics marketplace," said Joseph A. Sorge, MD, Chairman and CEO of Stratagene.

“This relationship with Max Planck Innovation supports our initiatives to develop molecular detection technologies, diagnostics tests and instruments for the molecular diagnostics market.”

Advertisement